
**ANNOUNCEMENT PURSUANT TO RULE 704(18)(C) OF THE LISTING MANUAL OF THE
SINGAPORE EXCHANGE SECURITIES TRADING LIMITED (“SGX-ST”)
DISPOSAL OF SHARES IN FINESTDAY LIMITED**

1. INTRODUCTION

The Board of Directors (the “**Board**”) of Thomson Medical Group Limited (the “**Company**” and its subsidiaries collectively the “**Group**”) wishes to announce that its wholly-owned subsidiary, Rowsley (Stox) Pte. Ltd. (“**RS**”) had on 9 November 2018 completed the sale of 1,200,000 issued and fully paid D ordinary shares of £1.00 each (the “**Sale Shares**”), comprising 50% of the capital of Finestday Limited (“**Finestday**”) and assigned shareholders loans to Finestday of two million pounds sterling (£2,000,000) (the “**Loan**”) (collectively the “**Disposal**”), pursuant to a sale and purchase agreement (“**SPA**”) entered into with Relentless Stox Investments Limited (the “**Purchaser**”) and Gary Alexander Neville (the “**Assignee**”) signed on the same day. The Company had invested in Finestday in 2016 in a joint-venture to develop the Stock Exchange Hotel in Manchester, England (the “**Hotel**”).

2. INFORMATION RELATING TO THE DISPOSAL

2.1 Rationale for the Disposal

The Group’s current businesses comprise the healthcare business and the real estate business.

Following the completion of the very substantial acquisition of the healthcare business, the Company’s focus is to develop and grow its healthcare business and the Company will assess options to divest its real estate portfolio (save for Vantage Bay Healthcare City) when such opportunity arises.

The Company’s business in real estate includes principally design, engineering, real estate development and hospitality. The Company has reviewed its business and decided to streamline its real estate business to focus on the consultancy business. The Disposal is made pursuant to such decision.

2.2 Information on the Purchaser and Assignee

The Purchaser is a private limited company incorporated in England and Wales and is majority controlled by the Assignee. The Assignee is a joint-venture partner and shareholder of Finestday.

3. CONSIDERATION FOR THE DISPOSAL

3.1 The aggregate consideration for the Disposal is £3,200,000 (the “**Consideration**”) comprising £1,200,000 for the Sale Shares, and £2,000,000 for the assignment of the Loan. This was arrived at following arm’s length negotiations on a “willing-buyer, willing-seller” basis, taking

into consideration the cost of developing the Hotel and the real estate and hospitality market in Manchester.

3.2 The Consideration will be paid in cash by the Purchaser and the Assignee in instalments, according to the terms of the SPA. On completion, the Sale Shares were transferred to the Purchaser and Finestday ceased to be a subsidiary of RS.

3.3 The net asset value of the Sale Shares as at 30 August 2018 was £1,030,000.

4. **FINANCIAL EFFECTS**

The Disposal is not expected to have any material impact on the net tangible assets and earnings per share of the Company for the financial year ending 31 December 2018.

5. **INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS**

None of the directors or controlling shareholders of the Company has any interest, direct or indirect, in the Disposal.

BY ORDER OF THE BOARD

HASAN MALIK
Company Secretary

12 November 2018

THOMSON MEDICAL GROUP LIMITED
Company Registration No. 199908381D
101 Thomson Road
#20-04/05 United Square
Singapore 207591
Tel: +65 6331 0188
Fax: +65 6331 0180
Website: www.thomsonmedicalgroup.com